SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Alexion Pharmaceuticals, Inc. (ALXN)
An SI Board Since October 1997
Posts SubjectMarks Bans Symbol
824 29 0 ALXN
Emcee:  Larry Liebman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
199This trash-hold of 5X peri-oper ckmb level is somehow lower than those ALXN willMiljenko Zuanic-12/3/2001
198Been meaning to get a copy of that. When you posted the link earlier I did not keokalani'nui-11/20/2001
197<i>Is there doubt that high ckmb correlates with mortality?</i> NotBiomaven-11/20/2001
196You have a good point. If it does not save lives, maybe FDA will not look favorkeokalani'nui-11/16/2001
195Wilder, Seems that I am entering here field without clear view. As you said, liMiljenko Zuanic-11/16/2001
194P3 has 3000 patients, is powered to show 30-35% drug benefit at ckmb>100. P2keokalani'nui-11/15/2001
193<<Hope I have not embarrassed myself. >> No, not at all. I appreciaMiljenko Zuanic-11/15/2001
192So to answer your question, moving from 60 - 70 placebo n is reduced 12% and drukeokalani'nui-11/15/2001
191<pre>Here are n, extrapolated by using a ruler on the AHA chart which was keokalani'nui-11/15/2001
190<<Those numbers for each ascending ckmb cutoff (placebo/drug) are 12%/37%,Miljenko Zuanic-11/15/2001
189Yes, thank you. Very compelling data. The AHA Guardian abstract I quoted from keokalani'nui-11/15/2001
188Wilder, Here's the abstract that I think is the one that they referred to Biomaven-11/15/2001
187Someone told me how to preserve the charts. So I will try my post again, since keokalani'nui-11/14/2001
186Thanks Jim. The reporter left off some key info, like p values and the limitatikeokalani'nui-11/14/2001
185Alexion drug gets OK for trials Abram Katz, Register Science Editor November 14Jim Oravetz-11/14/2001
184Sorry about the charts, a shame I couldn't figure out to format them. Fixedkeokalani'nui-11/13/2001
183Using the alxn chart at AHA, I pulled apart the ckmb numbers, extrapolating n frkeokalani'nui-11/13/2001
182<i>On a related matter, Dr. Bell continued, ``With the complete analysis okeokalani'nui-11/13/2001
181CHESHIRE, Conn., Nov. 8 /PRNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: Akeokalani'nui-11/8/2001
180I'm still here and still overinvested. The truth looms. Will I be knight orkeokalani'nui-11/1/2001
179CHESHIRE, Conn., Oct. 19 /PRNewswire/ -- Alexion Pharmaceuticals Inc. (Nasdaq: Anigel bates-10/19/2001
178Lenny Bell presented at Bear Stearns virtual conference this morning. Slides anIan@SI-9/26/2001
177Neurogen Starts Phase I Studies of Novel Anti-Inflammatory C5a Receptor Blocker keokalani'nui-9/24/2001
176I will be asleep, but at ~1:00am tomorrow (pdt), Scott Rollins presents results keokalani'nui-9/10/2001
175Would like to clarify one of my statements on neurocog improvement by pulling apkeokalani'nui-6/8/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News